

Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2

Jia Wang, ... , Maode Wang, Ichiro Nakano

J Clin Invest. 2020;130(9):5027-5027. <https://doi.org/10.1172/JCI142404>.

Expression of concern

Original citation: *J Clin Invest.* 2017;127(8):3075–3089. <https://doi.org/10.1172/JCI89092> Citation for this expression of concern: *J Clin Invest.* 2020;130(9):5027. <https://doi.org/10.1172/JCI142404> The Editors recently became aware of potential blot anomalies in Figures 1J, 2A, 3A, and 4D and Supplemental Figures 3A, 4C, and 6A. The Editors have requested an institutional investigation into this matter, and we will inform our readers of the outcome when the investigation is complete.

Find the latest version:

<https://jci.me/142404/pdf>



Expression of concern

Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2

Jia Wang, Peng Cheng, Marat S. Pavlyukov, Hai Yu, Zhuo Zhang, Sung-Hak Kim, Mutsuko Minata, Ahmed Mohyeldin, Wanfu Xie, Dongquan Chen, Violaine Goidts, Brendan Frett, Wenhao Hu, Hongyu Li, Yong Jae Shin, Yeri Lee, Do-Hyun Nam, Harley I. Kornblum, Maode Wang, and Ichiro Nakano

Original citation: *J Clin Invest*. 2017;127(8):3075–3089. <https://doi.org/10.1172/JCI89092>.

Citation for this expression of concern: *J Clin Invest*. 2020;130(9):5027. <https://doi.org/10.1172/JCI142404>.

The Editors recently became aware of potential blot anomalies in Figures 1J, 2A, 3A, and 4D and Supplemental Figures 3A, 4C, and 6A. The Editors have requested an institutional investigation into this matter, and we will inform our readers of the outcome when the investigation is complete.